The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A first-in-human phase I/II study of GFH375, a highly selective and potent oral KRAS G12D inhibitor in patients with KRAS G12D mutant advanced solid tumors.
 
Xinghao Ai
No Relationships to Disclose
 
Aiping Zhou
No Relationships to Disclose
 
Lin Wu
No Relationships to Disclose
 
Zhengbo Song
No Relationships to Disclose
 
Zhihua Li
No Relationships to Disclose
 
Heshui Wu
No Relationships to Disclose
 
Ying Yuan
No Relationships to Disclose
 
Hong Zong
No Relationships to Disclose
 
Lingjun Zhu
No Relationships to Disclose
 
Haitao Zhao
No Relationships to Disclose
 
Yuping Sun
No Relationships to Disclose
 
Zuoxing Niu
No Relationships to Disclose
 
Yu Wang
Employment - Genfleet Therapeutics
 
Haige Shen
Employment - Genfleet Therapeutics
Stock and Other Ownership Interests - Genfleet Therapeutics; Laekna Therapeutics
 
Huaqiang Zhu
Employment - Genfleet Therapeutics
 
Chanli Zheng
Employment - Genfleet Therapeutics
 
Shuang Wang
Employment - Genfleet Therapeutics
 
Congqiao Zhao
Employment - Genfleet Therapeutics
 
Zhao Cui
Employment - Genfleet Therapeutics
 
Shun Lu
Leadership - Innovent BIOLOGICS, INC; Shanghai Fosun; Simcere Zaiming
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; GenomiCare; Hutchison MediPharma; InventisBio Co. Ltd; Menarini; Pfizer; Roche; Simcere; Yuhan; Zai Lab
Speakers' Bureau - AstraZeneca; Hansoh Pharma; Hengrui Therapeutics; Roche
Research Funding - AstraZeneca (Inst); BeiGene (Inst); BMS (Inst); Hansoh (Inst); Hengrui Therapeutics (Inst); Hutchison MediPharma (Inst); Lilly Suzhou Pharmaceutical Co. (Inst); Roche (Inst)